208 related articles for article (PubMed ID: 35452553)
1. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models.
Raina K; Kant R; Prasad RR; Kandhari K; Tomar M; Mishra N; Kumar R; Fox JT; Sei S; Shoemaker RH; Chen Y; Maroni P; Agarwal C; Agarwal R
Mol Carcinog; 2022 Jul; 61(7):717-734. PubMed ID: 35452553
[TBL] [Abstract][Full Text] [Related]
2. Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during TMPRSS2-ERG (fusion)-driven prostate carcinogenesis.
Prasad RR; Mishra N; Kant R; Fox JT; Shoemaker RH; Agarwal C; Raina K; Agarwal R
Mol Carcinog; 2024 Jun; 63(6):1188-1204. PubMed ID: 38506376
[TBL] [Abstract][Full Text] [Related]
3. EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.
Zoma M; Curti L; Shinde D; Albino D; Mitra A; Sgrignani J; Mapelli SN; Sandrini G; Civenni G; Merulla J; Chiorino G; Kunderfranco P; Cacciatore A; Kokanovic A; Rinaldi A; Cavalli A; Catapano CV; Carbone GM
Nat Commun; 2021 Jul; 12(1):4147. PubMed ID: 34230470
[TBL] [Abstract][Full Text] [Related]
4. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
6. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
Linn DE; Bronson RT; Li Z
PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
[TBL] [Abstract][Full Text] [Related]
7. TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence.
Fang L; Li D; Yin J; Pan H; Ye H; Bowman J; Capaldo B; Kelly K
Cancer Gene Ther; 2022 Oct; 29(10):1463-1476. PubMed ID: 35393570
[TBL] [Abstract][Full Text] [Related]
8. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y
Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318
[TBL] [Abstract][Full Text] [Related]
9. Differential Effect of Non-Steroidal Anti-Inflammatory Drugs Aspirin and Naproxen against
Raina K; Kandhari K; Kant R; Prasad RR; Mishra N; Maurya AK; Fox JT; Sei S; Shoemaker RH; Bosland MC; Maroni P; Agarwal C; Agarwal R
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894421
[TBL] [Abstract][Full Text] [Related]
10. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.
Casey OM; Fang L; Hynes PG; Abou-Kheir WG; Martin PL; Tillman HS; Petrovics G; Awwad HO; Ward Y; Lake R; Zhang L; Kelly K
PLoS One; 2012; 7(7):e41668. PubMed ID: 22860005
[TBL] [Abstract][Full Text] [Related]
11. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
[TBL] [Abstract][Full Text] [Related]
12. Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels.
Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Lorente JA; Fumado L; Serrano L; Serrano S; Lloreta J; Hernández S
Prostate; 2015 Aug; 75(11):1216-26. PubMed ID: 25939480
[TBL] [Abstract][Full Text] [Related]
13. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA
Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961
[TBL] [Abstract][Full Text] [Related]
14. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.
Goel S; Bhatia V; Kundu S; Biswas T; Carskadon S; Gupta N; Asim M; Morrissey C; Palanisamy N; Ateeq B
Nat Commun; 2021 Sep; 12(1):5325. PubMed ID: 34493733
[TBL] [Abstract][Full Text] [Related]
16. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.
Lapointe J; Kim YH; Miller MA; Li C; Kaygusuz G; van de Rijn M; Huntsman DG; Brooks JD; Pollack JR
Mod Pathol; 2007 Apr; 20(4):467-73. PubMed ID: 17334351
[TBL] [Abstract][Full Text] [Related]
17. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
18.
Blee AM; He Y; Yang Y; Ye Z; Yan Y; Pan Y; Ma T; Dugdale J; Kuehn E; Kohli M; Jimenez R; Chen Y; Xu W; Wang L; Huang H
Clin Cancer Res; 2018 Sep; 24(18):4551-4565. PubMed ID: 29844131
[No Abstract] [Full Text] [Related]
19. TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer.
Yamoah K; Lal P; Awasthi S; Naghavi AO; Rounbehler RJ; Gerke T; Berglund AE; Pow-Sang JM; Schaeffer EM; Dhillon J; Park JY; Rebbeck TR
Prostate; 2021 Feb; 81(2):109-117. PubMed ID: 33141952
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]